# Imatinib Mesylate in Treating Patients With Myelofibrosis

> **NCT00245128** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00245128
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2007-03
- **Final completion:** 2011-10
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Per PI, results from another similar study were published prior to study analysis. Negative study results were published therefore analysis was not completed
- **Last updated:** 2012-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245128, "Imatinib Mesylate in Treating Patients With Myelofibrosis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00245128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*